Anatomical main group
H – SYSTEMISCHE HORMONPRÄPARATE, EXKL. SEXUALHORMONE UND INSULINE
17Decisions
19Patient groups
Added benefit by patient group
- Considerable1
- Minor2
- Non-quantifiable7
- Not proven9
Subgroups
- H01 HYPOPHYSEN- UND HYPOTHALAMUSHORMONE UND ANALOGA 9 decisions
- H02 CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG 3 decisions
- H03 SCHILDDRÜSENTHERAPIE 1 decision
- H05 CALCIUMHOMÖOSTASE 4 decisions
Decisions, newest first
- 2025-10-16EmcitateTiratricolNon-quantifiable
- 2025-06-05YseltyLinzagolixNot proven
- 2025-03-06YseltyLinzagolixNot proven
- 2024-10-02EladynosAbaloparatidNot proven
- 2024-07-04AgamreeVamorolonNon-quantifiable
- 2024-06-20YorvipathPalopegteriparatidNot proven
- 2024-05-16RyeqoRelugolix/Estradiol/NorethisteronNot proven
- 2024-05-02SogroyaSomapacitanNon-quantifiable: 2 of 2 patient groups
- 2024-03-07SkytrofaLonapegsomatropinNon-quantifiable
- 2022-09-15NgenlaSomatrogonNon-quantifiable
- 2022-07-21RayaldeeCalcifediolNot proven
- 2022-02-17RyeqoRelugolix/Estradiol/NorethisteronConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-01-07IsturisaOsilodrostatNon-quantifiable
- 2018-11-01AlkindiHydrocortisonNot proven
- 2017-11-17ParsabivEtelcalcetidNot proven
- 2015-06-18SigniforPasireotidMinor
- 2012-12-06SigniforPasireotidMinor
Data status: 2026-10-29